Because we have therapeutically aligned project teams, your clinical trial receives attention from experts who understand the unique needs of studies conducted in infectious disease clinical trials and vaccines. We are not guessing how to support your sites and patients, we know how because of our experienced staff. At Pharm-Olam, 79% of our CRAs and 84% of our project managers have specialized infectious disease and vaccine experience. We are not only experts in our field, we are experts in your clinical trial.
Deep Roots in Antibiotic Research:
As Infectious Disease CRO, we have expansive infectious disease experience, but especially deep roots in supporting anti-infective development. Our long and successful history in the anti-infective area of drug development, is demonstrated by supporting more than 50% of all antibiotics approved by FDA/EMA since 2010.
What’s more, we have executed numerous pivotal studies supporting marketing approvals for the following indications, to name a few:
![Scalable Delivery Ecosystem[x2]](https://www.pharm-olam.com/hs-fs/hubfs/assets/pattern-of-excellence/Scalable%20Delivery%20Ecosystem%5Bx2%5D.png?width=414&height=455&name=Scalable%20Delivery%20Ecosystem%5Bx2%5D.png)
Your infectious disease and vaccine study needs are global and so is our delivery ecosystem. We have established strategic relationships around the world, building a network of partners and vendors to support your unique requirements for infectious disease clinical trails and vaccine research, including:
Our work on this ecosystem is continuous and constantly expanding to ensure that you receive the most optimal delivery system for your infectious disease and vaccine studies. To learn more about our Expeditionary CRO capability to access Africa, Asia and South America, click the button below.
For more than 20 years, we have been working directly with federal agencies, contracting and conducting federally funded drug and vaccine research.
Our team has collaborated with many U.S. government agencies, including the National Institutes of Health (NIH), U.S. Department of Defense (DOD), Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC), among others. We also have worked extensively with non-government organizations (NGOs) and nonprofit organizations.
To learn how we can support your program from both a pre-award and post-award capacity, click the button below to visit our U.S. Government Federal Research Services page.
Conducting infectious disease and vaccine research is especially complicated. One incorrect end point can mean the difference between successfully meeting milestones or incurring costly delays and budget overages. That’s why we provide comprehensive program and protocol development consulting to ensure that your infectious disease and vaccine research is exceptionally well-planned and executed as efficiently as possible from day one.
When you work with our infectious disease and vaccines team, led by Dr. Slobodan Ilic, we review the development of your program across all functional areas to ensure the strictest adherence to protocol and regulatory requirements. In addition, Dr. Kelly McKee, whose infectious disease research career spans more than 40 years, is also available to oversee and consult on your development program.
Having our team of experts review and advise on your program and protocol development will streamline your project from beginning to end.
Pharm-Olam is the only Infectious Disease CRO and Vaccine CRO in the industry to leverage the full power of Medidata's Unified Platform, the Medidata Rave® Clinical Cloud. As a benefit to you, your study will have receive streamlined access to data, deeper data insights, and lead to better performance. By offering unmatched insight into your clinical trial data sources, you can make informed, evidence-based decisions that keep your study on track.
Learn more about how this technology improves the conduct of clinical research by visiting our Why Pharm-Olam page.
